Alvotech and Advanz Pharma submit proposed Eylea 8 mg biosimilar for regulatory review
The companies announced the first known worldwide regulatory submission for the proposed biosimilar.
Story updates
08:32:16 AM UTC
SquawkNews
Alvotech submitted AVT29, a proposed biosimilar to Eylea 8 mg, to the EMA as a line extension to its approved 2 mg aflibercept (Mynzepli). The company says this is the first known regulatory submission globally for an Eylea 8 mg biosimilar.Material DetailsContext by AI AnalystThis is an early regul…